INTRODUCTION: Previous studies have reported an association between μ-opioid receptor (OPRM1) genotype and smoking cessation, with some evidence that the strength of this association depends on dose of nicotine replacement therapy (NRT). We examined whether a single-nucleotide polymorphism in the OPRM1 gene is associated with cessation and whether this variant moderates the effects of higher doses of NRT on abstinence. METHODS: Participants were recruited from the practices of primary care physicians in the United Kingdom. Patients smoking an average of at least 10 cigarettes a day, who wanted to quit and were 18 years or older were eligible for inclusion. A total of N = 633 participants were recruited into the original trial, of whom complete data for pharmacogenetic analyses were available on n = 598. Logistic regression was used to test for the effects of OPRM1 genotype and NRT dose, including the genotype × dose interaction term, on smoking status at 4-week, and 26-week follow-up. Analyses were adjusted for potential confounders. RESULTS: There was no evidence of a genotype effect at either follow-up, and no evidence of a genotype × dose interaction effect. CONCLUSIONS: OPRM1 genotype may not affect the likelihood of smoking cessation, and it may not influence response to high- versus low-dose NRT. OPRM1 may have at most only a modest role in explaining cigarette smoking and cessation.
INTRODUCTION: Previous studies have reported an association between μ-opioid receptor (OPRM1) genotype and smoking cessation, with some evidence that the strength of this association depends on dose of nicotine replacement therapy (NRT). We examined whether a single-nucleotide polymorphism in the OPRM1 gene is associated with cessation and whether this variant moderates the effects of higher doses of NRT on abstinence. METHODS:Participants were recruited from the practices of primary care physicians in the United Kingdom. Patients smoking an average of at least 10 cigarettes a day, who wanted to quit and were 18 years or older were eligible for inclusion. A total of N = 633 participants were recruited into the original trial, of whom complete data for pharmacogenetic analyses were available on n = 598. Logistic regression was used to test for the effects of OPRM1 genotype and NRT dose, including the genotype × dose interaction term, on smoking status at 4-week, and 26-week follow-up. Analyses were adjusted for potential confounders. RESULTS: There was no evidence of a genotype effect at either follow-up, and no evidence of a genotype × dose interaction effect. CONCLUSIONS:OPRM1 genotype may not affect the likelihood of smoking cessation, and it may not influence response to high- versus low-dose NRT. OPRM1 may have at most only a modest role in explaining cigarette smoking and cessation.
Authors: Francesc Francès; Olga Portolés; Ana Castelló; Jose Antonio Costa; Fernando Verdú Journal: Bosn J Basic Med Sci Date: 2015-04-25 Impact factor: 3.363
Authors: Naji C Salloum; Erica L F Buchalter; Swati Chanani; Gemma Espejo; Mahjabeen S Ismail; Randy O Laine; Maysaa Nageeb; A Benjamin Srivastava; Nicholas Trapp; Ludwig Trillo; Erica Vance; Michael Wenzinger; Sarah M Hartz; Sean P David; Li-Shiun Chen Journal: Pharmacogenomics Date: 2018-06-19 Impact factor: 2.533
Authors: Tae-Hwi Schwantes-An; Juan Zhang; Li-Shiun Chen; Sarah M Hartz; Robert C Culverhouse; Xiangning Chen; Hilary Coon; Josef Frank; Helen M Kamens; Bettina Konte; Leena Kovanen; Antti Latvala; Lisa N Legrand; Brion S Maher; Whitney E Melroy; Elliot C Nelson; Mark W Reid; Jason D Robinson; Pei-Hong Shen; Bao-Zhu Yang; Judy A Andrews; Paul Aveyard; Olga Beltcheva; Sandra A Brown; Dale S Cannon; Sven Cichon; Robin P Corley; Norbert Dahmen; Louisa Degenhardt; Tatiana Foroud; Wolfgang Gaebel; Ina Giegling; Stephen J Glatt; Richard A Grucza; Jill Hardin; Annette M Hartmann; Andrew C Heath; Stefan Herms; Colin A Hodgkinson; Per Hoffmann; Hyman Hops; David Huizinga; Marcus Ising; Eric O Johnson; Elaine Johnstone; Radka P Kaneva; Kenneth S Kendler; Falk Kiefer; Henry R Kranzler; Ken S Krauter; Orna Levran; Susanne Lucae; Michael T Lynskey; Wolfgang Maier; Karl Mann; Nicholas G Martin; Manuel Mattheisen; Grant W Montgomery; Bertram Müller-Myhsok; Michael F Murphy; Michael C Neale; Momchil A Nikolov; Denise Nishita; Markus M Nöthen; John Nurnberger; Timo Partonen; Michele L Pergadia; Maureen Reynolds; Monika Ridinger; Richard J Rose; Noora Rouvinen-Lagerström; Norbert Scherbaum; Christine Schmäl; Michael Soyka; Michael C Stallings; Michael Steffens; Jens Treutlein; Ming Tsuang; Tamara L Wall; Norbert Wodarz; Vadim Yuferov; Peter Zill; Andrew W Bergen; Jingchun Chen; Paul M Cinciripini; Howard J Edenberg; Marissa A Ehringer; Robert E Ferrell; Joel Gelernter; David Goldman; John K Hewitt; Christian J Hopfer; William G Iacono; Jaakko Kaprio; Mary Jeanne Kreek; Ivo M Kremensky; Pamela A F Madden; Matt McGue; Marcus R Munafò; Robert A Philibert; Marcella Rietschel; Alec Roy; Dan Rujescu; Sirkku T Saarikoski; Gary E Swan; Alexandre A Todorov; Michael M Vanyukov; Robert B Weiss; Laura J Bierut; Nancy L Saccone Journal: Behav Genet Date: 2015-09-21 Impact factor: 2.805
Authors: Adam M Leventhal; Wonho Lee; Andrew W Bergen; Gary E Swan; Rachel F Tyndale; Caryn Lerman; David V Conti Journal: Drug Alcohol Depend Date: 2014-03-05 Impact factor: 4.492
Authors: Ewoud Schuit; Orestis A Panagiotou; Marcus R Munafò; Derrick A Bennett; Andrew W Bergen; Sean P David Journal: Cochrane Database Syst Rev Date: 2017-09-08